(Reuters) – The U.S. Food and Drug Administration said on Wednesday it was requesting makers of all versions of heartburn drug Zantac to remove the drugs from the market immediately due to the presence of a probable carcinogen.
French drugmaker Sanofi SA’s Zantac and some generic versions of the treatment, also known as ranitidine, have been recalled over the last year due to possible contamination with N-nitrosodimethylamine (NDMA).
